17. In developing a vaccine for a dangerous new strain of flu virus a pharmaceutical company incurs a very high fixed cost. The marginal cost of delivering the vaccine to patients, however, is negligible (consider it to be equal to zero). The pharmaceutical company holds the exclu -

sive patent to the vaccine. You are a regulator who must decide what price the pharmaceutical company is allowed to charge.